Ireland - English - HPRA (Health Products Regulatory Authority)

ge healthcare as - iodixanol - solution for injection - 320 mg i/mg millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; iodixanol

Ireland - English - HPRA (Health Products Regulatory Authority)

ge healthcare as - iodixanol - solution for injection - 270 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; iodixanol

Ireland - English - HPRA (Health Products Regulatory Authority)

ge healthcare as - iodixanol - solution for injection - 320 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; iodixanol

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 10 mg/ml - injection, suspension - excipient ingredients: carmellose sodium; polysorbate 80; benzyl alcohol; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - intra-articular: kenacort-a 10 injection (sterile triamcinolone acetonide suspension usp) is indicated for intra-articular or intrasynovial administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute non-specific tenosynovitis, post-traumatic osteoarthritis. intradermal: intralesional administration of kenacort-a 10 injection is indicated for the treatment of keloids, discoid lupus erythermatous, necrobiosis lipoidica diabeticorum, alopecia areata and localised hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus ( neurodermatitis), kenacort-a 10 injection also may be useful in cystic tumours of an aponeurosis or tendon ( ganglia).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 40 mg/ml - injection, suspension - excipient ingredients: benzyl alcohol; sodium chloride; polysorbate 80; carmellose sodium; water for injections; sodium hydroxide; hydrochloric acid - intramuscular: the intramuscular administration of kenacort-a 40 (sterile triamcinolone acetonide suspension usp) is indicated for systemic corticosteroid therapy in such conditions as allergic diseases, dermatoses, or generalised rheumatoid arthritis and other connective tissue disorders. intramuscular administration is particularly valuable in such conditions where oral corticosteroid therapy is not feasible. intra-articular: kenacort-a 40 injection is indicated for intra-articular or intrasynovial administration and for injections into tendon sheaths as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; post-traumatic osteoarthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - chadox1-s, quantity: 100000000000 vp/ml - injection, solution - excipient ingredients: histidine; magnesium chloride hexahydrate; sucrose; disodium edetate; polysorbate 80; sodium chloride; histidine hydrochloride monohydrate; ethanol absolute; water for injections - vaxzevria has provisional approval for the indication:,active immunisation of individuals greater than or equal to 18 years old for the prevention of coronavirus disease 2019 (covid-19) caused by sars-cov-2.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short term efficacy and safety data. continued approval is dependent upon the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium nitroprusside, quantity: 50 mg - injection, solution - excipient ingredients: water for injections - dbl? sodium nitroprusside injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium nitroprusside, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - sodium nitroprusside baxter concentrated injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: aluminium; water for injections; borax; sodium chloride - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; aluminium; sodium chloride; water for injections - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.